12 Week NMN Trials Show Modest Sleep Gains From NAD+ in Older Adults

September 28, 2026
Older adult participating in sleep research

Bottom line: NAD+ biology is genuinely linked to sleep regulation, and small human trials of NAD+ precursors show modest, population-specific improvements. A 12-week trial of 250 mg/day oral NMN in older adults reported better sleep quality scores, but effects vary by protocol and population, IV NAD+ has no controlled sleep trials behind it, and medical oversight matters for therapeutic use. Below: mechanisms, trial evidence, dosing advice, safety, and a clinician-supervised option.

TL;DR:

  • NAD+ precursors like NMN have shown modest improvements in sleep quality and daytime dysfunction in small, older adult studies over 12 weeks.
  • The strongest evidence comes from oral NMN at doses around 250 mg/day, with timing potentially impacting effectiveness, especially when taken in the evening.
  • Animal studies suggest NAD+ influences sleep pressure and efficiency through molecular mechanisms involving clock genes and SIRT1, but direct human evidence remains limited.
  • NAD+ supplements are regulated as foods, with safety data supporting doses up to 180 mg/day, but IV NAD+ lacks controlled sleep trials and carries higher costs and risks.
  • Personal sleep improvement is best approached through clinician-guided protocols, baseline tracking, and combining NAD+ strategies with established sleep hygiene practices.
Revive Meds
revive-meds.com
Explore Clinician-Supervised NAD+ Care
Revive Meds offers clinician-reviewed NAD+ and peptide therapies, with ongoing provider messaging throughout your treatment.

Explore NAD+ care

Table of Contents

How NAD+ connects to your circadian clock and sleep biology

NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme every cell needs to convert food into usable energy. It also acts as the fuel for a family of proteins called sirtuins, particularly SIRT1, which regulate gene expression, inflammation, and cellular repair. This dual role, part metabolic currency and part signaling molecule, is why NAD+ shows up in conversations about aging, energy, and increasingly, sleep.

The clock connection runs through SIRT1’s effect on core circadian genes. BMAL1 and PER2 are the molecular gears that keep your internal clock running on a roughly 24-hour cycle, and SIRT1 physically interacts with the machinery that turns these genes on and off. When NAD+ is abundant, SIRT1 activity rises, and the feedback loop between BMAL1 and PER2 tends to run more precisely. When NAD+ is scarce, that loop can drift, which may show up as fragmented sleep, shifted sleep timing, or a weaker distinction between daytime alertness and nighttime drowsiness. A narrative review of vitamin B3 and sleep describes this pathway and notes that NAD+ precursors can support clock gene performance, though it stops short of calling the human evidence definitive.

Illustration of NAD circadian feedback loop

Mitochondrial function ties into the same story. Sleep is when the brain and body do a large share of their metabolic housekeeping, clearing oxidative byproducts and restoring cellular energy reserves. NAD+ is central to that process because it feeds the mitochondrial pathways that generate ATP and neutralize oxidative stress. Less available NAD+ theoretically means less efficient overnight repair, which could translate into the kind of sleep that feels technically sufficient in hours but unsatisfying in quality.

Age is where this becomes concrete. NAD+ levels decline as people get older, and that decline tracks with the same years when sleep often becomes lighter and more fragmented. This is part of why most of the clinical trial interest in NAD+ precursors has focused on older adults rather than younger populations.

A few mechanistic points worth holding onto:

  • NAD+ acts as a cofactor for SIRT1, the sirtuin most closely tied to circadian gene regulation.
  • BMAL1 and PER2 form the clock’s feedback loop, and SIRT1 activity (dependent on NAD+) helps keep that loop on schedule.
  • Mitochondrial repair happens largely during sleep, and NAD+ availability affects how efficiently that repair runs.
  • NAD+ levels themselves oscillate with the sleep-wake cycle, rising and falling rather than sitting at a constant level throughout the day.

NAD+ levels naturally rise and fall across the 24-hour cycle, and this oscillation appears tied to the same clock genes that govern when you feel alert versus sleepy, according to the review of B3 and sleep mechanisms. That two-way relationship, the clock shaping NAD+ rhythms and NAD+ shaping the clock, is what makes this molecule interesting to sleep researchers rather than just longevity researchers. It also explains why the practical guidance later in this article pays attention to timing, not just dose.

For readers who want the mitochondrial side of this explained in more depth, mitochondrial health is covered separately, since it underlies both energy metabolism and the sleep story.

What human trials of NMN and NR actually found

The strongest human evidence on NAD+ and sleep comes from short trials of oral NMN (nicotinamide mononucleotide), a direct precursor to NAD+. The most cited study is a 12-week randomized, double-blind, placebo-controlled trial that gave older adults 250 mg/day of NMN and tracked sleep quality, fatigue, and physical performance. The treatment group showed lower PSQI (Pittsburgh Sleep Quality Index) global scores and reduced daytime dysfunction compared to placebo, with one reported analysis showing an effect size for drowsiness of d = 0.64, a moderate effect by conventional standards.

A separate trial measuring blood biomarkers alongside sleep outcomes found that 12 weeks of NMN intake raised blood NAD+ metabolites and improved specific PSQI domains, notably daytime dysfunction and global score, in older adults, with no major adverse events reported. Not every cohort responded the same way. Across the small pool of NMN sleep trials, some groups showed clear PSQI domain improvements while others showed no significant change, a pattern the same source describes as grounds for cautious optimism rather than a settled conclusion.

Safety and pharmacokinetic data add useful context even where sleep wasn’t the primary endpoint. A study in healthy, middle-aged Japanese men tested NMN doses between 100 and 500 mg and found the compound generally well tolerated, with blood NAD+ metabolites rising reliably and no significant adverse effects reported at these ranges over the study period.

NR (nicotinamide riboside), the other major NAD+ precursor studied in humans, has a thinner and more mixed sleep-specific record. The B3 and sleep review notes that NR and related precursors can enhance clock gene performance in preclinical work, and that human trials show improved sleep efficiency or quality in some populations, but the authors explicitly call for more research before drawing firm conclusions. Combination products pairing NR with other longevity compounds (sometimes marketed as NRPT formulations) haven’t produced sleep-specific trial data distinct from NR alone, so claims about them rest on the same limited NR evidence base.

Trial focus Dose and duration Reported sleep outcome
NMN in older adults 250 mg/day for 12 weeks Lower PSQI global score, reduced daytime dysfunction, drowsiness effect size d = 0.64
NMN with biomarker tracking 12 weeks, older adults Improved PSQI daytime dysfunction and global score, raised blood NAD+ metabolites
NMN safety and pharmacokinetics 100 to 500 mg, middle-aged men No significant adverse effects, reliable NAD+ metabolite increases, sleep not the primary endpoint

None of these trials are large by pharmaceutical standards, and several limitations apply across the board:

  • Sample sizes are small, typically in the dozens rather than hundreds, which limits how confidently results generalize.
  • Cohorts cluster in specific regions and age groups, mostly older adults in single-country studies, so findings may not extend to younger or more diverse populations.
  • Sleep outcomes rely on subjective questionnaires like the PSQI rather than objective measures such as polysomnography.
  • Dosing and timing vary across studies, making it hard to isolate an optimal protocol.
  • Female-specific data is thin in several of the available trials, leaving open questions about whether responses differ by sex.

The practical read: older adults with self-reported daytime dysfunction and below-average sleep quality are the group where NMN trials have shown the clearest, though still modest, benefit. Global PSQI score and daytime dysfunction are the two outcome measures that improved most consistently.

What animal studies reveal about NAD+ and sleep pressure

Before NMN and NR reached human sleep trials, the groundwork came from mouse studies that could measure sleep architecture directly with EEG rather than relying on questionnaires. The most relevant of these found that chronic dietary NR supplementation reduced time spent in NREM (non-rapid eye movement) sleep by approximately 17% in mice, while accelerating the discharge of what sleep scientists call Process S, the biological pressure that builds during wakefulness and gets released during sleep.

That finding is more nuanced than “less sleep is better.” The mice weren’t sleeping less because they were sleep-deprived. Instead, their sleep pressure appeared to build and resolve more efficiently, meaning they may have needed less total NREM sleep to clear the same accumulated sleep debt. The same study reported EEG correlates consistent with altered sleep homeostasis rather than disrupted or lower-quality sleep.

At the molecular level, the mechanistic story lines up with what’s seen in cell and tissue studies: PER2 nuclear translocation, the process by which this clock protein moves into the cell nucleus to regulate gene expression, and SIRT1-mediated chromatin changes, which affect how tightly DNA is packaged and how accessible clock genes are for transcription. Both processes depend on NAD+ availability, and both feed into the same BMAL1-PER2 feedback loop described earlier. This is the mechanistic bridge that let researchers move from “NAD+ affects the molecular clock in cell studies” to “NAD+ precursors are worth testing in living animals, then humans.”

A few things to keep in mind about this evidence:

  • Mouse sleep architecture and human subjective sleep quality are not the same measurement, so a 17% NREM reduction in mice doesn’t map directly onto a PSQI score in people.
  • EEG-based Process S changes are objective and precise, which is why animal data is valuable for building mechanistic hypotheses even though it can’t be applied one-to-one to humans.
  • The mouse data explains plausibility, not proof, it tells you why NAD+ precursors could plausibly change human sleep, not that they definitely will at any given dose.

The gap between “changed mouse EEG readings” and “improved human sleep satisfaction” is exactly where the small human trials described above try to close the loop, with partial, encouraging, but not conclusive success.

Choosing a form, a dose, and realistic timing expectations

If you’re weighing whether to try an NAD+ precursor for sleep, the practical questions come down to form, dose, timing, and route, and the evidence differs meaningfully across all four.

Forms in use today:

  1. NMN (nicotinamide mononucleotide) has the most direct human sleep trial data, including the PSQI improvements described in the 12-week trial and the biomarker study above, making it the best-studied oral option for this specific use.
  2. NR (nicotinamide riboside) has stronger mechanistic and preclinical sleep data, including the mouse Process S findings, but mixed and limited human sleep-specific results.
  3. Plain nicotinamide (niacinamide), a related B3 form, raises NAD+ through a different pathway and has not been tested in dedicated human sleep trials, so its sleep effects are inferred rather than demonstrated.
  4. NAD+ infusions (IV or injectable) deliver NAD+ directly rather than through a precursor, but no controlled trial has evaluated IV NAD+ for sleep outcomes specifically, leaving this route without direct evidence for this use.

Trial dosing for NMN has generally clustered around 250 mg/day over 8 to 12 weeks, the range used in the studies with positive PSQI signals. Over-the-counter supplement labeling varies widely and doesn’t always match trial doses, and it’s worth remembering that no NAD+ precursor is an FDA-approved treatment for insomnia or any other sleep disorder. Marketing claims about “curing” sleep problems go beyond what any of the current trials support.

Timing may matter more than most people assume. Trials that dosed NMN later in the day reported larger effect sizes on daytime dysfunction and overall sleep quality than morning-only dosing, a pattern that fits the circadian mechanism described earlier: if NAD+ availability interacts with the BMAL1-PER2 loop, timing the dose to align with the body’s evening wind-down phase is a more coherent strategy than dosing purely for convenience. This remains a plausible, trial-informed hypothesis rather than a settled protocol, and it’s the kind of decision worth making with a clinician rather than by guesswork.

On route, oral precursors carry actual randomized trial data behind them. IV NAD+ does not, and that absence of controlled evidence, not any specific documented harm, is the core reason to be cautious about paying for infusion-based protocols marketed for sleep. Readers considering either route can review dosing ranges by route before deciding what to discuss with a provider.

Expectations worth setting from the start: measurable changes in the available trials took 8 to 12 weeks, not days, and the improvements reported were modest and concentrated in specific domains, daytime dysfunction and PSQI global score, rather than a dramatic across-the-board transformation in sleep.

Pro Tip: Track your sleep with a simple diary or the PSQI questionnaire before starting any NAD+ precursor, so you have a real baseline to compare against at the 8 to 12 week mark instead of relying on memory.

Safety, regulation, and when oversight matters

In the United States, nicotinamide riboside has cleared a GRAS (Generally Recognized as Safe) notice for specified food uses, which is a food-safety designation, not drug approval. NAD+ precursors sold as supplements are regulated as supplements, not medications, which means claims about treating insomnia or any diagnosed sleep disorder haven’t been evaluated by the FDA in the way a prescription drug’s claims would be.

The FDA’s GRAS review for NR discussed toxicology data supporting a conservative tolerable intake proxy of roughly 3 mg/kg/day, which works out to about 180 mg/day for someone weighing 60 kg, according to the agency’s GRAS response letter. That figure comes from animal toxicology studies used to derive a no-observed-adverse-effect level, not from a human sleep trial, and it’s meant as a conservative safety ceiling rather than an effective dose.

Reported adverse effects across the human trials cited above have been minor, generally nothing beyond occasional mild gastrointestinal discomfort, and no major adverse events tied directly to NMN or NR at studied doses. Potential interactions deserve attention regardless: high-dose B3 compounds can interact with medications metabolized through similar pathways, and anyone on multiple prescriptions should have a clinician review the full list before adding a new supplement.

A few situations call for clinician involvement rather than a self-directed trial:

  • Pre-existing liver disease, since B3-family compounds are processed through the liver.
  • Pregnancy, where NAD+ precursor safety data in humans is limited.
  • Polypharmacy, meaning multiple existing prescriptions that could interact.
  • Severe or persistent insomnia, which may have an underlying cause that a supplement won’t address.
  • Interest in IV NAD+ or compounded formulations, given the lack of controlled trial data and the added cost and infusion-related risk involved, a point covered in more detail in the guidance on at-home NAD+ injections.

Who is likely to benefit, and how to structure a monitored trial

The clearest candidates for trying an NAD+ precursor for sleep are older adults reporting daytime dysfunction, people with metabolic contributors to poor sleep, such as declining mitochondrial efficiency, and anyone in a life stage where NAD+ depletion is a documented pattern rather than a guess, a shift often discussed alongside how sleep changes with age. People with no sleep complaints at all have little to gain from adding a precursor purely on a hypothesis.

A sensible, clinician-guided trial looks like this:

  1. Establish a baseline using the PSQI, a simple sleep diary, and optionally actigraphy if objective tracking is available.
  2. Review the plan with a clinician, covering current medications, liver function, and any conditions that warrant extra caution.
  3. Start the chosen precursor at an evidence-based dose, typically the 250 mg/day range used in the NMN trials, with timing discussed rather than assumed.
  4. Reassess at 8 to 12 weeks, the window used in the trials that reported PSQI improvements, comparing the same baseline measures.
  5. Monitor for adverse effects and, where relevant, liver enzymes, particularly at higher or compounded doses.

NAD+ precursors are reasonably viewed as one component of a broader sleep strategy, not a replacement for it. Cognitive behavioral therapy for insomnia (CBT-I) has a substantially longer evidence base for chronic sleep difficulty, and addressing metabolic contributors, weight, activity level, blood sugar regulation, often moves the needle further than any single supplement.

How clinician-supervised NAD+ care is actually delivered

Revive Meds structures NAD+ access around a full medical intake reviewed by a licensed clinician before anything is prescribed, rather than a checkout page that ships a product on request. That review is where the safety considerations above, liver history, current medications, pregnancy status, get checked against the specific NAD+ protocol being considered.

That combination, clinical review first and pharmacy-grade sourcing second, is the structural answer to a problem this article has flagged repeatedly: supplement labeling varies, and IV or infusion products sold without oversight carry no controlled trial evidence behind them.

Ongoing care doesn’t stop once the package arrives. Unlimited provider messaging is included, so dose adjustments, questions about timing, or new symptoms can go directly to the clinician managing the protocol rather than sitting unanswered. That matters most in exactly the scenarios flagged earlier: polypharmacy, liver history, or a patient trying to figure out whether an effect at week 6 is worth continuing to week 12.

None of this amounts to a guarantee that NAD+ therapy will resolve a given patient’s sleep complaints. The trial evidence is real but modest, and individualized assessment, not a one-size-fits-all protocol, is what determines whether NAD+ is even the right tool for a particular person’s sleep problem.

Does NAD+ interact with caffeine, melatonin, or sleep medications

There’s no dedicated human trial data on how NAD+ precursors interact with common sleep aids, so what follows is a matter of plausible pharmacology rather than confirmed findings. Caffeine and NAD+ precursors don’t share an obvious metabolic conflict, but caffeine’s own effect on sleep onset and depth is well established, and stacking a late-day precursor dose with late-day caffeine muddies any attempt to judge whether a sleep change came from the supplement or the coffee.

Melatonin works through an entirely different pathway, signaling darkness to the brain, rather than the NAD±dependent clock gene mechanisms described earlier, so the two aren’t known to conflict directly. Combining them isn’t documented as unsafe, but it also hasn’t been tested together in trials, which means any combined effect is unverified rather than confirmed safe.

Prescription sleep medications and high-dose B3 compounds both get processed through the liver, which is the practical reason to loop in a clinician before combining an NAD+ precursor with an existing sleep prescription. This is less about a known dangerous interaction and more about the simple fact that nobody has studied the combination closely enough to rule one out.

Everyday habits that shape your NAD+ levels and sleep

Diet, exercise, and light exposure all influence NAD+ availability and, by extension, the clock mechanisms this article has described throughout. Diets adequate in niacin and tryptophan support the body’s own NAD+ synthesis pathway, while chronic caloric excess and poor metabolic health are associated with lower cellular NAD+ over time.

Exercise activates some of the same sirtuin pathways that NAD+ fuels, and regular physical activity is one of the few well-established levers for both mitochondrial efficiency and sleep quality, reinforcing the mitochondrial link covered in the mechanisms section. Light exposure, particularly morning sunlight and reduced blue light in the evening, directly entrains the BMAL1-PER2 clock loop, the same loop NAD+ and SIRT1 help regulate from the inside.

None of these habits require a supplement, and none of them are optional add-ons to an NAD+ protocol, they’re the foundation a precursor works on top of. A person with an erratic light schedule, minimal activity, and poor diet is unlikely to see the modest gains reported in the NMN trials simply by adding a pill, because the underlying clock machinery those trials measured is also shaped by these daily inputs.

The honest read on NAD+ and sleep hype

The evidence for NAD+ precursors and sleep is real, but the gap between what trials show and what marketing implies is wide. A 12-week trial with a moderate effect size on daytime dysfunction is meaningfully different from “restores your sleep,” and treating the two as equivalent is where most of the public conversation goes wrong.

What’s underrated here is timing and consistency, not dose size. The circadian mechanism connecting NAD+ to BMAL1 and PER2 suggests that when you take a precursor may matter as much as how much, yet most discussion fixates on milligrams. What’s overrated is IV NAD+ for sleep specifically. It’s the most expensive route and the one with zero controlled sleep trials behind it, which makes it the weakest evidence-to-cost ratio of any option covered here.

If you take one thing from this article, it should be that oral NMN at trial-tested doses, evaluated over a real 8 to 12 week window with a baseline PSQI score, is the only version of this intervention with human sleep data behind it worth acting on, and even that comes with modest expectations attached.

— Amy

Getting started with clinician-supervised NAD+ care

If the trial evidence above has you curious about trying an NAD+ precursor under real oversight rather than guessing at supplement labels, Revive Meds runs the process through a full intake, clinician review, and then compounding and home delivery once a protocol is approved.

Revive Meds

Eligibility depends on your health history and current medications, which is exactly what the intake and clinician review are built to check before anything ships. The available routes, including NAD+ nasal spray, NAD+ injection, and NAD+ flex dose tablets, give a clinician options to match to your specific situation rather than defaulting to one format for everyone.

Nothing here is a promise that NAD+ therapy will fix a given sleep problem. Baseline evaluation and clinician oversight are required parts of the process, not a formality, and the honest starting point is a conversation with a provider about whether NAD+ fits your case at all. If it does, the next step is straightforward: explore NAD+ options and start an intake.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

Why do some people feel better on NAD+ supplements?

People often report feeling more energetic on NAD+ precursors because NAD+ is central to how cells generate usable energy through mitochondrial function. Trials of oral NMN have also linked it to modest improvements in sleep quality and reduced daytime dysfunction, which could independently explain reports of feeling sharper during the day.

Can NAD+ supplements make it harder to fall asleep?

There’s no trial evidence that NAD+ precursors cause insomnia, and the human studies available report improved rather than worsened sleep quality scores. Taking a dose very late at night alongside stimulants like caffeine could plausibly interfere with sleep onset, though this hasn’t been tested directly.

What are the downsides of taking NAD+ supplements?

Reported adverse effects in human NMN trials have been minor, mostly mild digestive discomfort, with no major adverse events at studied doses. The bigger downside is regulatory: NAD+ supplements aren’t FDA-approved treatments for insomnia, IV NAD+ has no controlled sleep trials behind it, and quality varies widely across unregulated products.

What nutrient deficiency is commonly linked to poor sleep?

Sleep difficulty has many possible causes, and no single nutrient deficiency explains most cases. NAD+ availability, which depends partly on dietary niacin and tryptophan intake, is one biological factor researchers have studied, with declining NAD+ levels linked to weaker circadian clock function as people age.